June 25, 2007 — Arrowhead Research Corp. has changed the name of its new wholly-owned nanobioscience subsidiary from C Sixty Acquisition Corp. to Tego BioSciences Corp. The subsidiary acquired the assets of C Sixty, Inc. in March 2007, and is now focused on the development of new protective products based on the anti-oxidant properties of modified buckministerfullerenes (fullerenes or buckyballs). Tego is initially developing products to reduce oxidative damage caused by sun exposure, radiation therapy, and chemotherapy and mitigate complications associated with organ transplantation and tissue engineering.

“Tego is set to commence preclinical animal studies in collaboration with the National Cancer Institute this summer,” said R. Bruce Stewart, Chairman of Arrowhead. “Tego is in the process of assembling a business and technical team with expertise in nanoparticle-based therapeutics and skin care products.”

The preclinical studies will be performed in the NCI’s Nanotechnology Characterization Lab (NCL) to measure the ability of a Tego fullerene formulation to protect against harmful side effects of two anti-cancer drugs, cisplastin and adriamycin. The first stage of the studies will use NCL’s resources, with follow on funding from Tego, as appropriate.